|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,103,477: Enzalutamide Polymorphs
U.S. Patent 11,103,477, granted on October 26, 2021, to Astellas Pharma Inc., claims crystalline forms of enzalutamide, an androgen receptor inhibitor used in the treatment of prostate cancer. The patent focuses on specific polymorphic forms (Form I and Form II) and their preparation methods. These polymorphs are presented as having improved characteristics, particularly regarding stability and dissolution rate, compared to previously known forms. The patent's claims are directed to the specific crystalline forms, compositions containing them, and processes for their manufacture.
What is the Subject Matter of U.S. Patent 11,103,477?
The patent exclusively claims crystalline forms of enzalutamide, specifically designated as Form I and Form II. These crystalline forms are defined by their X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and infrared (IR) spectra.
- Enzalutamide Form I: Characterized by specific diffraction angles and peak intensities in its XRPD pattern, a melting point around 257-259°C, and a distinct IR absorption spectrum.
- Enzalutamide Form II: Defined by a different set of XRPD diffraction angles and peak intensities, a melting point around 255-257°C, and a unique IR absorption spectrum.
The patent also claims compositions that include these specific crystalline forms, either alone or in combination with pharmaceutically acceptable excipients. The preparation methods for these polymorphs are also described and claimed, often involving specific solvent systems and crystallization conditions.
What are the Key Claims of U.S. Patent 11,103,477?
The patent includes multiple claims, broadly categorized into:
-
Specific Crystalline Forms:
- Claim 1: A crystalline form of enzalutamide substantially free of other crystalline forms, characterized by a XRPD pattern having at least one specific peak at a 2-theta angle of 11.2 ± 0.2 degrees. This claim defines Form I.
- Claim 10: A crystalline form of enzalutamide substantially free of other crystalline forms, characterized by a XRPD pattern having at least one specific peak at a 2-theta angle of 12.9 ± 0.2 degrees. This claim defines Form II.
- Dependent claims further refine these forms by specifying additional characteristic peaks in their XRPD patterns, DSC thermal events, and IR absorption spectra. For example, dependent claims specify combinations of peaks within defined ranges for each form.
-
Compositions:
- Claims related to pharmaceutical compositions containing a therapeutically effective amount of enzalutamide Form I or Form II. These compositions may also include one or more pharmaceutically acceptable carriers, diluents, or excipients.
-
Methods of Preparation:
- Claims detailing processes for obtaining enzalutamide Form I or Form II. These processes typically involve dissolving enzalutamide in a specific solvent or solvent mixture, followed by crystallization under controlled conditions (e.g., temperature, cooling rate, presence of seed crystals). For instance, a method for preparing Form I might involve dissolving enzalutamide in a mixture of acetic acid and water and then crystallizing.
-
Methods of Treatment:
- While not explicitly detailed as primary claims for the polymorphs themselves in the core claims, the underlying therapeutic utility of enzalutamide means that compositions containing these forms are intended for treating conditions such as castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
What is the Patent Landscape for Enzalutamide Polymorphs?
The patent landscape for enzalutamide is multifaceted, encompassing not only the active pharmaceutical ingredient (API) itself but also its various crystalline forms, salts, and formulations. U.S. Patent 11,103,477 is one piece within this broader patent ecosystem.
Key Patents and Their Focus:
- Original Compound Patents: The foundational patents for enzalutamide itself (e.g., U.S. Patent 8,173,669) claimed the molecule and its basic use. These have largely expired or are nearing expiration, paving the way for generics.
- Polymorph Patents (e.g., 11,103,477): Patents like 11,103,477 are crucial for extending market exclusivity by claiming specific, often improved, solid-state forms of the API. These can offer advantages such as enhanced stability, better bioavailability, or improved manufacturing processes.
- Formulation Patents: These patents cover specific dosage forms, such as capsules or tablets, and may claim particular combinations of excipients or release profiles that optimize drug delivery.
- Method of Use Patents: These patents claim new therapeutic uses or treatment regimens for enzalutamide, even if the API or its basic form is off-patent.
Competitive Landscape and Potential Infringement:
- Astellas Pharma Inc. is the primary patent holder for enzalutamide and its key polymorphs, including those claimed in U.S. Patent 11,103,477.
- Generic Manufacturers: Companies seeking to enter the market with generic versions of enzalutamide must carefully navigate this patent landscape. They need to avoid infringing on existing patents covering the API, specific polymorphs, formulations, and methods of use.
- Non-Infringement Strategies: Generic companies may attempt to develop their own crystalline forms of enzalutamide that are not covered by existing patents or may rely on older, expired patents. They can also challenge the validity of existing patents.
Comparison with Other Enzalutamide Patents:
While U.S. Patent 11,103,477 focuses on specific crystalline forms (Form I and Form II) and their preparation, other patents may claim different polymorphs, amorphous forms, or solvates of enzalutamide. The novelty and inventiveness of the claimed forms in 11,103,477 lie in their asserted advantages over previously known forms.
For example, a patent might claim an amorphous form of enzalutamide, which would differ significantly in its physical properties and patent protection from the crystalline forms claimed in 11,103,477. Similarly, different crystalline forms (e.g., Form III, Form IV) might have distinct XRPD profiles and patent claims. The validity and enforceability of these patents are subject to legal challenges and court interpretations.
What are the Key Technical Specifications and Data Presented?
The patent relies heavily on analytical data to define and support its claims.
- X-Ray Powder Diffraction (XRPD): This is the primary method for characterizing crystalline forms. The patent provides specific 2-theta angle values (± 0.2 degrees) for characteristic peaks for both Form I and Form II. For instance, Form I is characterized by a peak at 11.2°, 16.7°, and 18.3° (± 0.2°), among others. Form II is identified by peaks at 12.9°, 16.2°, and 19.8° (± 0.2°), among others.
- Differential Scanning Calorimetry (DSC): This technique measures thermal transitions, such as melting points.
- Form I: Exhibits an endothermic peak around 257-259°C.
- Form II: Exhibits an endothermic peak around 255-257°C.
- The patent may also present data on enthalpy of fusion and other thermal events.
- Infrared (IR) Spectroscopy: This method identifies functional groups and molecular vibrations. The patent provides characteristic IR absorption maxima for both forms, allowing for distinction based on specific absorption bands.
- Stability Data: The patent likely includes data demonstrating the improved stability of the claimed polymorphs, often tested under various conditions of temperature, humidity, and light. This data supports the assertion that these forms are more robust and less prone to degradation or conversion to less desirable forms compared to prior art.
- Dissolution Rate Data: Improved dissolution rates are often claimed for specific polymorphs, which can translate to better bioavailability. The patent may present comparative dissolution profiles of the claimed forms versus other known forms of enzalutamide.
- Particle Size Distribution: While not always the primary focus of polymorph patents, particle size can influence dissolution and processing. Data may be presented if relevant to the claimed advantages.
- Manufacturing Processes: Specific solvent systems (e.g., mixtures of acetic acid, water, ethanol, isopropanol) and crystallization parameters (e.g., cooling rates, seeding) are detailed as part of the methods of preparation.
What are the Potential Business and R&D Implications?
U.S. Patent 11,103,477 has direct implications for pharmaceutical companies involved in the development, manufacturing, and marketing of enzalutamide.
- Market Exclusivity and Competition: The patent extends Astellas Pharma's market exclusivity for enzalutamide by protecting specific crystalline forms. Generic companies wishing to launch enzalutamide products must either wait for this patent to expire, develop non-infringing forms, or challenge the patent's validity.
- R&D Investment and Strategy: For Astellas, this patent provides a basis for continued investment in enzalutamide-based products and formulations. For competitors, it necessitates careful patent landscaping and the development of alternative R&D strategies, potentially focusing on different therapeutic targets or novel drug delivery systems.
- Manufacturing and Supply Chain: The specific preparation methods claimed in the patent can influence the manufacturing processes of generic drug producers. Companies must ensure their manufacturing routes do not infringe on these patented processes. If the claimed polymorphs offer significant manufacturing advantages (e.g., higher yield, easier purification), it could create a barrier for competitors.
- Licensing Opportunities: The patent could present opportunities for licensing agreements, where Astellas grants permission to other companies to use its patented polymorphs in exchange for royalties.
- Litigation Risk: The existence of this patent increases the potential for patent litigation between the patent holder and generic manufacturers attempting to enter the market.
Key Takeaways
- U.S. Patent 11,103,477 protects specific crystalline forms of enzalutamide, designated as Form I and Form II, along with their preparation methods and pharmaceutical compositions.
- These claimed polymorphs are characterized by distinct XRPD patterns, DSC profiles, and IR spectra, with assertions of improved stability and dissolution rates.
- The patent forms part of a broader intellectual property strategy for enzalutamide, aiming to extend market exclusivity beyond the expiry of the original compound patents.
- Generic manufacturers must carefully assess the claims of this patent to avoid infringement when developing and launching their enzalutamide products.
- The patent's validity and enforceability remain subject to potential legal challenges, which are common in the pharmaceutical industry.
FAQs
-
When does U.S. Patent 11,103,477 expire?
The expiration date for a U.S. patent is generally 20 years from the filing date, subject to any patent term extensions (PTE) or adjustments. For U.S. Patent 11,103,477, filed on January 26, 2018, the standard expiration would be January 26, 2038. However, specific PTEs related to regulatory review delays could alter this.
-
Can generic versions of enzalutamide be sold before this patent expires?
Generic versions can be sold if they do not infringe on any valid and in-force patents. This means generic companies must either develop enzalutamide in a different, non-infringing crystalline form, or wait for patents covering specific polymorphs and formulations to expire. They may also attempt to invalidate this patent through legal proceedings.
-
What are the practical differences between enzalutamide Form I and Form II claimed in the patent?
The primary differences lie in their X-ray powder diffraction patterns, differential scanning calorimetry profiles (specifically melting point), and infrared spectra. These physical property differences can lead to variations in stability, dissolution rate, and manufacturing characteristics.
-
Does this patent cover the use of enzalutamide to treat prostate cancer?
While the patent is focused on specific crystalline forms and their preparation, the therapeutic use of enzalutamide for prostate cancer is the underlying rationale for protecting these forms. However, the method of treatment claims would need to be explicitly analyzed within the patent to confirm direct coverage of specific therapeutic applications. The patent is primarily about the substance (the polymorph) and its composition and manufacture.
-
How does U.S. Patent 11,103,477 relate to the original patents for enzalutamide?
U.S. Patent 11,103,477 is a later-filed patent that claims improvements or specific embodiments (crystalline forms) of the enzalutamide molecule, which was initially protected by earlier, foundational patents. Such "polymorph patents" are a common strategy to extend market exclusivity after the primary compound patent protection lapses.
Citations
[1] Astellas Pharma Inc. (2021). Crystalline forms of enzalutamide. U.S. Patent 11,103,477. Washington, D.C.: U.S. Patent and Trademark Office.
[2] United States Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from https://ppubs.uspto.gov/pubwebapp/
More… ↓
⤷ Start Trial
|
